[144] Incyte Genomics Inc SEC Filing

Rhea-AI Filing Summary

Form 144 notice for Incyte Genomics Inc (INCY): The filer reported a proposed sale of 598 common shares via Morgan Stanley Smith Barney on NASDAQ, with an aggregate market value of $50,812.06 and an approximate sale date of 09/02/2025. The shares were acquired the same day, 09/02/2025, by stock option exercise from the issuer and paid for in cash. The filer also disclosed six prior sales in the past three months totaling 7,384 shares for gross proceeds of $490,810.62 across dates from 06/03/2025 to 08/15/2025. The filer attests they are not aware of any undisclosed material adverse information.

Positive

• Transaction transparency: Filing clearly discloses acquisition method (stock option exercise), payment in cash, broker, and planned sale date
• Timely reporting: Multiple recent insider sales and the current proposed sale are documented, supporting regulatory compliance

Negative

• Insider selling activity: Six reported sales in the past three months totaling 7,384 shares could be viewed negatively by some investors
• No 10b5-1 plan disclosed: The filing does not state a trading plan adoption date, so sales may not be under a pre-established plan

Insights

Securities Analyst

TL;DR Insider exercised options and filed to sell 598 shares; multiple recent disposals total 7,384 shares over three months.

This filing documents a routine Rule 144 disposition following a same-day stock option exercise, with the broker listed as Morgan Stanley Smith Barney and the sale planned on NASDAQ. The filing also provides a clear track record of recent sales by the same person: six transactions from June through August 2025 totaling 7,384 shares and roughly $490,810.62 in proceeds. For investors, this is an explicit disclosure of insider liquidity events; it does not by itself indicate company performance changes because the document contains no operational or financial results.

Corporate Governance Expert

TL;DR The notice is a compliance disclosure showing insider option exercise then planned Rule 144 sale, plus multiple recent sales.

The form conforms to Rule 144 reporting requirements by specifying acquisition method (stock option exercise), payment in cash, broker details, and amounts. The repeated sales over a short period may warrant monitoring for pattern analysis but are standardly reported to satisfy securities law obligations. No allegations, restrictions, or trading-plan dates are provided, and the filer affirms no undisclosed material adverse information. The filing lacks any indication of Rule 10b5-1 trading-plan adoption or exemptions.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	598	50812.06	195276145	09/02/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	09/02/2025	Stock Option Exercise	Issuer			598	09/02/2025	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
SHEILA DENTON 1801 Augustine Cut-Off Wilmington DE 19803	Common	08/15/2025	277	24046.37
SHEILA DENTON 1801 Augustine Cut-Off Wilmington DE 19803	Common	08/04/2025	598	45310.46
SHEILA DENTON 1801 Augustine Cut-Off Wilmington DE 19803	Common	07/16/2025	785	53662.60
SHEILA DENTON 1801 Augustine Cut-Off Wilmington DE 19803	Common	07/15/2025	3330	232633.80
SHEILA DENTON 1801 Augustine Cut-Off Wilmington DE 19803	Common	07/02/2025	599	41097.39
SHEILA DENTON 1801 Augustine Cut-Off Wilmington DE 19803	Common	06/03/2025	1795	122060.00

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What did the Form 144 filed for INCY disclose?

The filing reports a proposed sale of 598 common shares on NASDAQ via Morgan Stanley Smith Barney with an aggregate market value of $50,812.06 and acquisition by stock option exercise on 09/02/2025 paid in cash.

How many shares has the insider sold recently for INCY?

The filer disclosed six sales from 06/03/2025 to 08/15/2025 totaling 7,384 shares for gross proceeds of $490,810.62.

Which broker is handling the proposed INCY sale?

The broker listed is Morgan Stanley Smith Barney LLC Executive Financial Services located at 1 New York Plaza, New York, NY.

Were the shares being sold acquired recently or long-held?

The 598 shares in the proposed sale were acquired the same day (09/02/2025) by stock option exercise and paid for in cash.

Does the Form 144 state the filer has undisclosed material information?

No; the filer signed the notice representing they do not know of any material adverse information about the issuer that has not been publicly disclosed.